Treatment of Dermatitis in Pregnancy
For dermatitis during pregnancy, start with emollients as the foundation, then use topical corticosteroids (specifically prednisolone-based preparations) as first-line therapy, with topical calcineurin inhibitors as an alternative for sensitive areas; if systemic therapy is required, cyclosporine A is the preferred agent, while azathioprine can be continued if already established pre-pregnancy.
Topical Therapy Approach
First-Line: Emollients and Topical Corticosteroids
- Emollients are universally safe and should be applied 1-3 times daily as the foundation of all treatment regimens 1
- Topical corticosteroids are the primary medical treatment during pregnancy and are generally considered safe 2, 3
- Apply to active lesions as needed for disease control
- Can be used 1-2 times weekly to previously involved skin after stabilization to prevent flares 4
Second-Line Topical Options
Topical calcineurin inhibitors (tacrolimus 0.03-0.1% ointment, pimecrolimus 0.1% cream):
- Pregnancy Category C but can be used when benefits outweigh risks 1
- Particularly useful for facial and intertriginous areas where corticosteroid atrophy is a concern
- Apply 2-3 times weekly for maintenance after disease control 4
- Most common side effect is burning/itching that typically decreases with continued use
- Not recommended for nursing mothers as both are found in human milk 1
Phototherapy
- UV light therapy is safe during pregnancy and can be added when topical therapy is insufficient 2, 3
- No evidence of harm to the fetus
Systemic Therapy Algorithm
When skin-directed approaches (topicals and/or phototherapy) fail to control moderate-to-severe disease, systemic therapy requires dermatology specialist input 5.
First-Line Systemic: Cyclosporine A
- Cyclosporine A is the preferred systemic agent during pregnancy 2, 3
- Safe for both mother and fetus based on extensive transplant literature
- Effective for severe atopic dermatitis requiring systemic control
Second-Line Systemic: Azathioprine
- Can be used in combination with corticosteroids 6
- Continue if already established pre-pregnancy rather than switching 2
- Low teratogenicity risk; widely used in transplant, IBD, and lupus pregnancies 6
- Dose: typically used at 1.5-2.5 mg/kg/day based on pemphigus data 7
Oral Corticosteroids
Prednisolone is the corticosteroid of choice if systemic steroids are needed 6:
- 90% inactivated by the placenta, minimizing fetal exposure
- No significant increased risk of stillbirth, preterm delivery, or congenital malformations
- Potential for intrauterine growth retardation with prolonged use
- Avoid betamethasone and dexamethasone - these cross the placenta more readily and have greater fetal effects 6
Emerging Option: Dupilumab
- Not generally recommended due to limited human pregnancy data 2
- However, emerging evidence suggests probable safety 8, 9:
- Meta-analysis of 115 pregnancies showed 18.9% spontaneous abortion rate (within general population range)
- No congenital malformations reported
- Mean exposure duration 27.5 weeks
- Consider only after careful risk-benefit assessment and shared decision-making
- Case reports show rapid improvement in severe cases 9
Contraindicated Medications
Absolutely avoid these agents:
- Mycophenolate mofetil - known fetal risks 6
- Methotrexate - teratogenic, contraindicated 6, 2
- Cyclophosphamide - known fetal risks 6
- JAK inhibitors - not recommended 2
- Rituximab - crosses maternofetal barrier; manufacturer advises against pregnancy for 1 year post-therapy 6
Antihistamines for Pruritus
When antihistamine therapy is necessary 10:
- Chlorphenamine (chlorpheniramine) is often chosen in the UK due to long safety record
- Loratadine and cetirizine are FDA Pregnancy Category B (no evidence of fetal harm)
- Avoid hydroxyzine - specifically contraindicated in early pregnancy
- Best to avoid all antihistamines in first trimester if possible, though none proven teratogenic in humans
Key Clinical Pitfalls
- Wrong corticosteroid choice: Using betamethasone or dexamethasone systemically instead of prednisolone increases fetal exposure unnecessarily
- Delaying specialist referral: Moderate-to-severe disease requiring systemic therapy needs early dermatology input 5
- Stopping effective pre-pregnancy therapy: If already on azathioprine with good control, continuing is safer than switching
- Inadequate emollient use: This foundation is often underutilized despite universal safety
- Avoiding all treatment: Uncontrolled severe dermatitis affects maternal quality of life and sleep, which has its own pregnancy risks